My career goal is to develop my expertise in the intersectional GPCR researches in science and industry. I have been deeply engaged in the GPCR field for 16 years, achieving innovative milestones in academic research and translational breakthroughs.  Ligand Recognition and Regulation Mechanisms: I have conducted in-depth exploration into the precise recognition and regulation mechanisms of ligands for important disease-related targets. This work provides profound insights into the molecular mechanisms of drug action and guides new drug discovery (Nature 2023; Neuron 2022; Protein Cell 2023; Sci Adv 2024; Nat Commun 2024; Science 2011; Structure 2017 etc.). Deciphering Undruggable GPCR Targets: I have unraveled the activation mechanisms and structural basis of atypical and hard-to-target GPCRs, such as orphan receptors and Frizzled receptors. This research lays the foundation for discovering the drug potential of these targets and for ligand discovery (Nature 2020; Nature 2018; Nat Commun 2023, 2017; Cell Discovery 2024, 2023; J Med Chem 2023; Cell Research 2021, etc.). Class A GPCR Dimerization: My work on the apelin receptor has for the first time demonstrated the structural basis of Class A GPCR dimerization, revealing the prominent roles of orthosteric pocket, G protein binding cleft, and dimer interface as hotspots for drug intervention (Nat Struct Mol Biol 2022; Structure 2017, etc.).These systematic structural and functional studies address unresolved scientific challenges in the GPCR field, providing a solid foundation for the discovery of new targets, mechanisms, and drugs, thereby driving the innovation of new drugs from 0 to 1.About the Translational Research that I have conducted: In 2011, I co-founded RuiYi (later renamed Bird Rock Bio, acquired by the US-listed company Skye in August 2023), where I led the development of the advanced GPCR antigen platform iCAPS. This effort advanced the development of Nimacimab, the world's first negative modulatory antibody targeting the cannabinoid receptor CB1, which is currently in clinical trials for the treatment of obesity and metabolic diseases. At the end of 2020, I initiated the founding of JIKANG Therapeutics and completed its first round of financing in October 2022. JIKANG leverages a world-leading GPCR structure and antibody drug research team to develop innovative biologics targeting multiple GPCRs, aiming to address critical issues in weight loss and metabolic disease treatment.